Aescap Life Sciences

With a portfolio manager that has over 30 years of experience investing in the biotech / life sciences market, Aescap Life Sciences provides investors the chance to invest into the future winners of this industry. An investment in the fund will not only allow for a good return on investment, it also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.

The fund has a focused portfolio, investing in approximately 20 companies. In order to reduce the risks of investing in this sector, the fund diversifies its portfolio over many disease areas, different phases of company development and geographical areas.

Read more about our strategy here.

The fund’s objective is to make an average minimum Annual Net Return (after deduction of costs) of 20% over the mid-term (4-5 years). For wealth managers there is no minimum subscription amount,, though the minimum subscription per time is EUR 10.000,-. Investors can enter and exit the fund twice a month.

ISIN Code Aescap Life Sciences: NL0012343958

Bloomberg: AESCAPI NA Equity